FDA Clears First-in-Class PBGENE-DMD to Begin Phase 1/2 Trial in Duchenne Muscular Dystrophy Precision BioSciences has received FDA clearance to launch a phase 1/2 trial of PBGENE-DMD in ambulatory DMD.

PBGENE-DMD, Precision BioSciences’ investigational in vivo gene editing therapy for ambulatory patients with Duchenne muscular dystrophy (#DMD), has cleared a key regulatory milestone.

Read more: https://bit.ly/4aUZkXn

#PBGENEDMD #GeneTherapy #MedTwitter